First Case of Paraphimosis as a Severe Complication of Monkeypox.

Since May 2022, the monkeypox (MPX) virus has represented an emerging issue due to outbreaks in non-endemic areas. This report presents the first case of paraphimosis caused by an MPX infection during the outbreak. The patient accessed the emergency department for a sudden onset of swelling of the penis and paraphimosis caused by MPX lesions that brought about stenosis of the foreskin. He therefore underwent a dorsal slit procedure with resolution. No antiviral therapy was required. A multidisciplinary approach should be preferred for the management of MPX, due to the possibility of uncommon and disseminated presentations.

Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Peyronie's disease (PD) is a chronic disorder involving the tunica albuginea surrounding the corpora cavernosa of the penis. A conservative treatment is indicated in the first stage of disease. The aim of this study was to assess the therapeutic impact and possible side effects of treatment with pentoxifylline (PTX) in combination with other antioxidants in 307 patients with early-stage PD. Patients were subdivided into three groups: A, B, and C. Both groups, A and B, comprising of 206 patients, underwent treatment, whereas Group C was the control group (n=101). Treatment lasted 6 months and included the following: Group A: PTX 400 mg twice a day + propolis 600 mg/d + blueberry 160 mg/d + vitamin E 600 mg/d + diclofenac 4% gel twice/a day + PTX 100 mg via perilesional penile injection/every other week (12 injections in all); Group B: the same treatment as Group A except for the penile PTX injections. After the 6-month treatment course, we obtained the following results: actual mean decrease in plaque volume -46.9% and -24.8% in Group A and B, respectively (P<0.0001); mean curvature reduction -10.1° and -4.8°, respectively (P,0.0001); resolution of pain in 67.6% and 67.2% of cases, respectively (P=0.961); recovery of normal penile rigidity in 56.09% and 23.5% of cases, respectively (P=0.005). After 6 months, progression of disease was observed in all patients belonging to Group C: plaque volume +123.3%; curvature +15.7°; no recovery of penile rigidity. The statistically significant results of our study show that multimodal treatment with PTX in association with other antioxidants and topical diclofenac is efficacious in treating early-stage PD. Furthermore, treatment proved to be more effective when PTX was administered both orally and by penile injection. No serious adverse effects occurred.

Bilateral nerve sparing robotic-assisted radical prostatectomy is associated with faster continence recovery but not with erectile function recovery compared with retropubic open prostatectomy: the need for accurate selection of patients.

Robotic-assisted radical prostatectomy (RARP) shows measurable advantages, compared to conventional open surgery, even if some aspects are, still, under debate. The aim of this study was to compare the potency recovery rate of patients with clinically localised prostate cancer treated by bilateral nerve-sparing (BNS) RARP or retropubic radical prostatectomy (RRP), and secondarily, the urinary continence recovery evaluation and the oncological efficacy. All patients treated with BNS-RARP or BNS-RRP for clinically localised prostate cancer, performed by a single dedicated surgeon, between January 2004 and December 2008, were enrolled in this non-randomised prospective comparative study. The International Index of Erectile Function (IIEF) and erection hardness score (EHS), in the form of a questionnaire, were self-administered to each patient pre-operatively and after 12 months. The presence of surgical margins was considered as oncological outcome measure. Eighty-two patients underwent BNS-RARP while 48 underwent BNS-RRP. For BNS-RARP and BNS-RRP the median operative time was 221 and 103 min, respectively (P<0.001; df=128; t=721.43),and intra-operative blood loss was 280 and 565 ml, respectively (P<0.001; df=128; t=1742.44). At a mean follow-up period of 12.4±2.3 months, 12 patients (25%) in the BNS-RRP group and 22 (26.8%) in the BNS-RARP group were considered potent with or without drugs (P=0.81). Moreover, we did not find any statistically significant difference between the 2 groups in terms of IEFF and EHS scores after treatment (17.21 vs. 16.98; P=0.16 and 2.1 vs. 2.0; P=0.54). On the other hand, statistically significant differences between the 2 groups were found in terms of faster urinary continence recovery and the presence of positive surgical margins (P<0.001, P=0.009). Shorter catheterization duration (7 vs. 3 days) and post-operative hospital stays (8 vs. 4 days; P<0.001) were found in the BNS-RARP group compared to the BNS-RRP group. In conclusion, our results demonstrate that BNS-RARP does not improve erectile function recovery compared to open radical prostatectomy; however, it significantly improves urinary continence and decreases the presence of positive surgical margins.

Prognostic role of cell apoptotic rate in prostate cancer: outcome of a long-time follow-up study.

The tumour apoptotic pattern is described as a good predictor of outcome in patients with prostate cancer (PCa). So far no authors have evaluated the role of apoptotic characteristics in patients who have undergone radical prostatectomy (RRP) alone. The aim of the present study is to estimate the prognostic role of the apoptotic index (AI) in a group of patients with prostatic adenocarcinoma subjected to RRP with no adjuvant therapy. Fifty patients underwent RRP according to standardised techniques and the surgical specimens were analysed histologically. In order to evaluate the AI and correlate these results with the follow-up data, we used a standardised apoptotic regulatory terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine-triphosphate-biotin nick end-labelling technique (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). The mean follow-up period was 66 months. Significant correlations were found between the AI and pathological features, such as stage (p<0.001) and grade (p<0.001). Out of 50 patients, 13 (26%) had biochemical recurrence and clinical disease progression, with an AI of 1.93 (range, 0.76-5.22), while 37 patients (74%) who did not report any disease progression, had an AI of 0.58 (range, 0.1-3.12). Furthermore, the AI significantly correlated with status at the end of follow-up (r=0.75, p=0.002), these data being confirmed by Kaplan-Meier curve analysis (p<0.001). On multivariate analysis, the AI proved to be an independent prognostic factor of progression-free probability (p<0.001). Our results highlight the utility of AI analysis in assessing the probability risk of clinical progression in PCa patients who are treated with RRP.

Detection rate of ultrasound vs CT scan in clinical staging accuracy of renal tumors pT1NxMx.

OBJECTIVE: Renal ultrasound is very important in the diagnosis of renal tumors. MATERIAL AND METHODS: From January 2000 to Jannuary 2005 we retrospectively examined the records of 116 patients, 37 women and 79 men (mean age 54 years, range 22-77), who underwent radical nephrectomy for kidney cancer in clinical stage CT1N0M0. 2.5 cm was the tumor dimension limit between the nephron sparing surgical technique and radical nephrectomy. We subdivided the sample into 2 groups, the first of 45 patients with tumor lesions smaller than 2.5 cm and the second with tumor lesions between 2.5 cm and 7 cm in diameter all patients underwent preoperative staging including ultrasound scan (ETG) and computer tomography scan (CT). RESULTS: Ultrasound has showed 35% sensitivity and 49% specificity for lesions under 2.5 cm in diameter, and 65% sensitivity and 75% specificity and 80% specificity for lesions under 2.5 and 80% sensitivity and 95% specificity for lesions between 2.5 and 7 cm. CONCLUSIONS: Ultrasound is the first step in the staging of renal cancer before surgery; to assess. 2.5 and 7 in diameter CT scan is the gold standard for solid and cystic lesions.

Penile Doppler ultrasound assessment of the cavernous arteries.

OBJECTIVE: To evaluate the possible relationship between the basal and dynamic diameter of the cavernous arteries and altered peak diastolic (PDV) and systolic values (PSV) in patients undergoing penile Doppler ultrasound for differential diagnosis of erectile dysfunction (ED). MATERIALS AND METHODS: From December 2003 to December 2004 we examined 132 consecutive patients suffering from erectile dysfunction and 30 controls. All patients underwent penile Doppler ultrasound in basal and dynamic conditions and all the examinations were performed by measurements of the cavernous arteries diameters in basal and dynamic conditions. RESULTS: In the 30 healthy controls the mean cavernous arteries diameter was 0.82 mm (range 0.6-1.3 mm) on the right and 0.8 mm (range 0.5-1.25 mm) in basal conditions vs 1.30 mm (range 0.9-1.6 mm) on the right and 1.25 on the left (range 0.9 -1.60 mm) in dynamic conditions after injection of 10 microg. In the 132 patients with a diagnosis of organic ED, the mean diameter was 0.70 mm (range 0.3-1.3 mm) on the right and 0.76 mm (range 0.3-1.24) on the left in basal conditions vs 1.21 mm (range 0.8-1.93 mm) on the right and 1.24 mm (range 0.9-1.66 mm) on the left in dynamic conditions after injection of 10 microg. CONCLUSION: In our experience, assessment of the cavernous arteries in basal and dynamic conditions provides important additional data. Altered basal and dynamic values are predictive of anomalous PDV and PSV findings.

[Role of power Doppler in the differential diagnosis between organic and functional cavernovenous insufficiency in patients with erectile maintenance deficiency]. / Ruolo del power Doppler nella diagnosi differenziale tra incompetenza cavernovenosa organica e funzionale nei pazienti con deficit del mantenimento dell'erezione.

Dynamic penile eco colorDoppler (ECDP) shows limits of specificity in case of differential diagnosis between functional (adrenergic hypertone) and organic cavernovenous incompetence. The aim of this study is the evaluation of a new flow chart for venogenic erectile dysfunction diagnosis, including power Doppler (PD), avoiding the repetition of ECD with higher concentrations of PGE1. In fact this procedure is invasive, often painful and burdened by a consistent risk of priapism. Patients suspected of caverno-venous incompetence underwent PD during the ECD. 85 of them showed high telediastolic velocity but normal systolic peak flow. All these patient underwent PGE1 redosing, to a maximum of 40 micrograms. Patients with still suspicious ECD were administered RigiScan. 63 patients over 85 had good PD, while 22 had bad PD. Of the 63 patients with good PD, 60 (95%) had normal ECD after redosing, while in 3 (5%) of them the telediastolic velocity remained high. In these 3 patients RigiScan showed normal nocturnal rigidity in 2 cases, abnormal in 1. 18 patients (82%) of the 22 with bad PD never showed improvement of ECD and RigiScan resulted altered in 15. In our opinion concordance between 10 micrograms ECD and PD avoids redosing in demonstrating organic venogenic erectile dysfunction. If PD is good but ECD is altered, 10 micrograms re-dosing could help in differentiating organic or functional erectile dysfunction. The diagnostic flow chart, then, should always include PD.

[Tolerability to transperineal prostatic biopsy based on the number of specimens]. / Tollerabilità della biopsia prostatica transperineale in base ai numeri dei prelievi eseguiti.

Prostate biopsy is a fundamental step in the diagnostic flow chart of prostate cancer. We have evaluated the influence of the number of cores taken on the tolerability and morbidity of the transperineal ultrasound-guided prostate biopsy. We have compared a group of 240 pts undergone 16 core prostate biopsy to an historical cohort of 100 pts undergone 10 core prostate biopsy. All the patients in both groups have been investigated about tolerability and morbidity of the procedure. No significant differences emerge between the two groups, and then we conclude that the number of cores taken does not influence the safety and compliance to the transperineal biopsy. This is a significant advantage compared to transrectal biopsy, as the number of cores influences the detection rate of prostate carcinoma.